Apimeds Pharmaceuticals US (APUS) Income towards Parent Company (2024 - 2025)

Apimeds Pharmaceuticals US (APUS) posted Income towards Parent Company of -$7.3 million for Q4 2025, down 305.91% on a QoQ basis from -$1.8 million in Q3 2025, and down 1797.17% year-over-year from $429099.8 in Q4 2024.

Apimeds Pharmaceuticals US (APUS) Income towards Parent Company (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US's Income towards Parent Company history runs 2 years deep, the most recent figure standing at -$7.3 million for Q4 2025.

  • Quarterly Income towards Parent Company fell 1797.17% year-over-year to -$7.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$12.2 million (down 730.98% YoY) and the FY2025 annual result came in at -$14.5 million, down 498.81% from the prior year.
  • Income towards Parent Company was -$7.3 million for Q4 2025 at Apimeds Pharmaceuticals US, down from -$1.8 million in the prior quarter.
  • Across five years, Income towards Parent Company topped out at -$296473.0 in Q1 2024 and bottomed at -$7.3 million in Q4 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 89.28 Bn 87.42 Bn -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn
6 RedHill Biopharma 22.11 Bn 22.11 Bn -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn
10 Apimeds Pharmaceuticals US 62.67 Mn 62.67 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 -7.28 Mn
Sep 30, 2025 -1.79 Mn
Jun 30, 2025 -2.67 Mn
Mar 31, 2025 -402,397.00
Dec 31, 2024 -383,864.00
Sep 30, 2024 -332,521.00
Jun 30, 2024 -449,363.00
Mar 31, 2024 -296,473.00